Looking after the overlooked
Theratechnologies is a commercial-stage biopharmaceutical company. We currently market prescription products in the United States, Europe and Canada. Our commercialized products and our research pipeline focus on specialized therapies addressing unmet medical needs in HIV and oncology.
The Company operates in a highly competitive and regulated field. We must constantly be creative and resourceful in finding innovative solutions that enable the Company to make the right decisions in a timely manner.
There are many challenges in our field. Theratechnologies' employees do not shy away from a challenge and demonstrate resilience, drive and determination in finding innovative solutions and achieving the Company's goals.
We are fully committed to market innovative therapies for orphan medical conditions. Our commitment also translates to our shareholders by continuously ensuring the growth of the Company.
Our commercialized products
Theratechnologies currently commercializes three products in the field of HIV. Trogarzo® is approved in the United States and Europe. EGRIFTA SV® is only approved in the United States. EGRIFTA® is approved in the United States, Canada and Mexico but is no longer available in the United States.
Latest Press Releases